Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
Fuente:
Wiley Open Access
Salvato in:
| Autori principali: | Kostas Stamatopoulos, Sarka Pavlova, Othman Al‐Sawaf, Thomas Chatzikonstantinou, Christina Karamanidou, Gianluca Gaidano, Florence Cymbalista, Arnon P. Kater, Andy Rawstron, Lydia Scarfò, Paolo Ghia, Richard Rosenquist |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2024
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Documenti analoghi
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia
di: Elisa Lenti, et al.
Pubblicazione: (2025)
di: Elisa Lenti, et al.
Pubblicazione: (2025)
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
di: Gian Matteo Rigolin, et al.
Pubblicazione: (2024)
di: Gian Matteo Rigolin, et al.
Pubblicazione: (2024)
Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
di: Arnon P. Kater, et al.
Pubblicazione: (2024)
di: Arnon P. Kater, et al.
Pubblicazione: (2024)
Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020
di: Lina van der Straten, et al.
Pubblicazione: (2024)
di: Lina van der Straten, et al.
Pubblicazione: (2024)
Extracellular vesicles from chronic lymphocytic leukemia cells promote leukemia aggressiveness by inducing the differentiation of monocytes into nurse‐like cells via an RNA‐dependent mechanism
di: Nathan Dubois, et al.
Pubblicazione: (2025)
di: Nathan Dubois, et al.
Pubblicazione: (2025)
Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience
di: Paolo Ghia, et al.
Pubblicazione: (2025)
di: Paolo Ghia, et al.
Pubblicazione: (2025)
Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
di: Raúl Córdoba, et al.
Pubblicazione: (2026)
di: Raúl Córdoba, et al.
Pubblicazione: (2026)
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
di: Thomas Chatzikonstantinou, et al.
Pubblicazione: (2024)
di: Thomas Chatzikonstantinou, et al.
Pubblicazione: (2024)
NK‐type large granular lymphocyte leukemia comes of age
di: Gianpietro Semenzato, et al.
Pubblicazione: (2025)
di: Gianpietro Semenzato, et al.
Pubblicazione: (2025)
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
di: Idanna Innocenti, et al.
Pubblicazione: (2024)
di: Idanna Innocenti, et al.
Pubblicazione: (2024)
First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis
di: Paolo Ghia, et al.
Pubblicazione: (2024)
di: Paolo Ghia, et al.
Pubblicazione: (2024)
Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B‐cell‐related epigenetic imprinting and genetic alterations
di: Stella Charalampopoulou, et al.
Pubblicazione: (2026)
di: Stella Charalampopoulou, et al.
Pubblicazione: (2026)
Chronic lymphocytic leukemia with IGH :: BCL3 ‐translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape
di: Cosima Drewes, et al.
Pubblicazione: (2026)
di: Cosima Drewes, et al.
Pubblicazione: (2026)
CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience
di: Riccardo Bomben, et al.
Pubblicazione: (2024)
di: Riccardo Bomben, et al.
Pubblicazione: (2024)
IL21—STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemia
di: Rosita Del Prete, et al.
Pubblicazione: (2026)
di: Rosita Del Prete, et al.
Pubblicazione: (2026)
Comparative analysis of macrophage feeder systems reveals distinct behaviors and key transcriptional shifts in chronic lymphocytic leukemia cells via coculture
di: Viktoria Kohlhas, et al.
Pubblicazione: (2025)
di: Viktoria Kohlhas, et al.
Pubblicazione: (2025)
Robust and cost‐effective CRISPR/Cas9 gene editing of primary tumor B cells in Eµ‐TCL1 model of chronic lymphocytic leukemia
di: Rosita Del Prete, et al.
Pubblicazione: (2024)
di: Rosita Del Prete, et al.
Pubblicazione: (2024)
3D Tumor microenvironment interaction reveals AP‐1 complex regulation and contact‐mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia
di: Jana Lindacher, et al.
Pubblicazione: (2025)
di: Jana Lindacher, et al.
Pubblicazione: (2025)
Loss of CYLD promotes splenic marginal zone lymphoma
di: Athanasios Pseftogas, et al.
Pubblicazione: (2025)
di: Athanasios Pseftogas, et al.
Pubblicazione: (2025)
Unveiling relative lymphopenia and elevated monocyte‐to‐lymphocyte count as novel independent adverse prognostic factors in chronic myelomonocytic leukemia (CMML)—Proposal of the objective prognostic index for CMML (OPIC)
di: Xavier Calvo, et al.
Pubblicazione: (2026)
di: Xavier Calvo, et al.
Pubblicazione: (2026)
Monitoring outcomes in patients treated by ATMPs
di: Kostas Konstantopoulos
Pubblicazione: (2025)
di: Kostas Konstantopoulos
Pubblicazione: (2025)
Long‐term outcome of 2‐year survivors after allogeneic hematopoietic cell transplantation for acute leukemia
di: Marion Larue, et al.
Pubblicazione: (2024)
di: Marion Larue, et al.
Pubblicazione: (2024)
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
di: André Baruchel, et al.
Pubblicazione: (2025)
di: André Baruchel, et al.
Pubblicazione: (2025)
Inflammatory signaling in the pathogenesis of acute myeloid leukemia
di: Artemis Margrith Baumann, et al.
Pubblicazione: (2025)
di: Artemis Margrith Baumann, et al.
Pubblicazione: (2025)
Improved post‐transplant outcomes since 2000 for Ph‐positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party
di: Ali Bazarbachi, et al.
Pubblicazione: (2025)
di: Ali Bazarbachi, et al.
Pubblicazione: (2025)
De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria
di: Peter Johnstone, et al.
Pubblicazione: (2025)
di: Peter Johnstone, et al.
Pubblicazione: (2025)
Impact of the kinetics of circulating anti‐BCMA CAR‐T cells and normal lymphocytes on the outcome of MM patients
di: Sara Gutiérrez‐Herrero, et al.
Pubblicazione: (2025)
di: Sara Gutiérrez‐Herrero, et al.
Pubblicazione: (2025)
Hyperdiploid acute lymphoblastic leukemia in children with LZTR1 germline variants
di: Lisa Zipper, et al.
Pubblicazione: (2024)
di: Lisa Zipper, et al.
Pubblicazione: (2024)
Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
di: Rebeqa Gunnarsson, et al.
Pubblicazione: (2025)
di: Rebeqa Gunnarsson, et al.
Pubblicazione: (2025)
Chronic graft‐versus‐host disease in long‐term survivors of childhood leukemia
di: Paul Saultier, et al.
Pubblicazione: (2026)
di: Paul Saultier, et al.
Pubblicazione: (2026)
Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute myeloid leukemia
di: Francesco Leonetti, et al.
Pubblicazione: (2025)
di: Francesco Leonetti, et al.
Pubblicazione: (2025)
HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
di: Sophie Le Grand, et al.
Pubblicazione: (2025)
di: Sophie Le Grand, et al.
Pubblicazione: (2025)
Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia
di: Hansen J. Kosasih, et al.
Pubblicazione: (2025)
di: Hansen J. Kosasih, et al.
Pubblicazione: (2025)
Correction to “Influence of donor–recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation”
Pubblicazione: (2024)
Pubblicazione: (2024)
HLA diversity is associated with TKI response and treatment‐free remission in chronic myeloid leukemia
di: Charles Toulemonde, et al.
Pubblicazione: (2025)
di: Charles Toulemonde, et al.
Pubblicazione: (2025)
Neuroinflammatory changes in acute myeloid leukemia: Evidence for blood–brain barrier disruption and glial activation
di: Marta Febo, et al.
Pubblicazione: (2026)
di: Marta Febo, et al.
Pubblicazione: (2026)
Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term results
di: Josep‐Maria Ribera, et al.
Pubblicazione: (2024)
di: Josep‐Maria Ribera, et al.
Pubblicazione: (2024)
Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients
di: Anna Pia Enblad, et al.
Pubblicazione: (2025)
di: Anna Pia Enblad, et al.
Pubblicazione: (2025)
Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B‐ALL, or T‐ALL
di: Roger Mulet‐Lazaro, et al.
Pubblicazione: (2025)
di: Roger Mulet‐Lazaro, et al.
Pubblicazione: (2025)
Dynamic evolution of TCF3‐PBX1 leukemias at the single‐cell level under chemotherapy pressure
di: Mira Kusterer, et al.
Pubblicazione: (2025)
di: Mira Kusterer, et al.
Pubblicazione: (2025)
Documenti analoghi
-
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia
di: Elisa Lenti, et al.
Pubblicazione: (2025) -
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
di: Gian Matteo Rigolin, et al.
Pubblicazione: (2024) -
Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
di: Arnon P. Kater, et al.
Pubblicazione: (2024) -
Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020
di: Lina van der Straten, et al.
Pubblicazione: (2024) -
Extracellular vesicles from chronic lymphocytic leukemia cells promote leukemia aggressiveness by inducing the differentiation of monocytes into nurse‐like cells via an RNA‐dependent mechanism
di: Nathan Dubois, et al.
Pubblicazione: (2025)